Therma Bright (TSE:THRM) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Therma Bright Inc. has announced its portfolio company InStatin’s new agreement with Mountain West Research to conduct a study aimed at enhancing the delivery of an innovative statin inhalant for asthma and COPD treatment. This research is a significant step towards the development of more effective respiratory therapies and is expected to support upcoming Phase 1 human trials. The company’s investment in InStatin aligns with the growing asthma treatment market, projected to reach USD 39.04 billion by 2032.
For further insights into TSE:THRM stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money